The world's first CDK2/4/6 inhibitor, developed by Chia Tai Tianqing Pharmaceutical Group, a subsidiary of Sino Biopharmaceutical, was officially approved for market launch on Thursday. CDK2/4/6 ...

The initiation of GLP-1 agonists was associated with a lower risk for Alzheimer’s disease and related dementias than the initiation of DPP-4 inhibitors in patients with diabetes undergoing ...

Please provide your email address to receive an email when new articles are posted on . Treatment with sodium-glucose cotransporter-2 inhibitors for type 2 diabetes may reduce the risk for rheumatoid ...

For people with chronic kidney disease (CKD) (long-term damage to the kidneys that reduces their ability to filter blood), also having diabetes (a lifelong condition that causes a person's blood sugar ...

ABSTRACT: Objective: This study compared the pharmacokinetic and safety profiles of two fixed-dose combinations (FDCs) and the mean ratios of the test to reference ...

5 Catholic Kwandong University College of Medicine Department of Medical Science, Gangneung-si, The Republic of Korea Background Dipeptidyl peptidase-4 inhibitors (DPP-4is) have been reported to ...

CLINICAL QUESTION: Do sodium-glucose cotransporter-2 (SGLT-2) inhibitors, as add-on therapy for diabetes, increase the risk of amputations, stent placement, or revascularization surgeries compared ...

Cardio-cerebrovascular diseases are increasingly prevalent worldwide, with pathological changes in the heart and brain reinforcing each other. Diabetes is a major driver of comorbidity between these ...

1. In this target trial emulation, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) did not significantly affect the risk of dementia compared with dipeptidyl peptidase-4 inhibitors (DPP4is) ...